Document Detail


Open-label extension study of flibanserin in women with hypoactive sexual desire disorder.
MedLine Citation:
PMID:  23057791     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Hypoactive Sexual Desire Disorder (HSDD) is a common form of Female Sexual Dysfunction characterized by low sexual desire that causes distress or interpersonal difficulty.
AIM: This 52-week open-label extension study aimed to assess the safety and tolerability of flibanserin, a postsynaptic 5-HT(1A) agonist/5-HT(2A) antagonist, in women with HSDD.
METHODS: Women with HSDD who had completed a trial of flibanserin or flibanserin placebo received flexible-dose flibanserin (50 or 100 mg once daily at bedtime [qhs] or 25 or 50 mg twice daily [bid]) for 52 weeks.
MAIN OUTCOME MEASURES: Primary end points were: proportions of women with somnolence, sedation, fatigue, dizziness, nausea, and vomiting (adverse events [AEs] known to be associated with flibanserin); discontinuations due to AEs; and serious AEs. Secondary end points included change from baseline in Female Sexual Distress Scale-Revised total and Item 13 scores and Female Sexual Function Index (FSFI) total and desire domain score scores. FSFI total scores were used to classify women into FSFI remitters (FSFI score >26.55, indicating no clinical sexual dysfunction) and FSFI non-remitters (FSFI score <26.55).
RESULTS: Of the 1723 women who received flibanserin, 962 (55.8%) completed 12 months' treatment, and 883 women were exposed to flibanserin 100 mg qhs for ≥180 days. Somnolence, sedation, fatigue, dizziness, nausea, and vomiting were reported by 15.8, 1.6, 7.6, 6.9, 6.3, and 1.4% of participants, respectively. A total of 185 participants (10.7%) discontinued due to AEs. Serious AEs were reported by 1.2% of participants. At study end, 42% of baseline non-remitters had improved their FSFI score to remission level. The proportion of baseline FSFI remitters in remission rose from 83% at week 4 to a stable value of ∼90%.
CONCLUSION: Flibanserin was well tolerated. Sexual function improved in women who were not FSFI remitters at baseline, and was maintained in those who were remitters at baseline.
Authors:
Christopher Jayne; James A Simon; Leslie V Taylor; Toshio Kimura; Lynna M Lesko;
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2012-10-11
Journal Detail:
Title:  The journal of sexual medicine     Volume:  9     ISSN:  1743-6109     ISO Abbreviation:  J Sex Med     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-04     Completed Date:  2013-05-24     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  101230693     Medline TA:  J Sex Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3180-8     Citation Subset:  IM    
Copyright Information:
© 2012 International Society for Sexual Medicine.
Affiliation:
Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA. chrisjayne41@yahoo.com
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00441558
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Benzimidazoles / administration & dosage*,  adverse effects*
Dizziness / chemically induced
Dose-Response Relationship, Drug
Drug Administration Schedule
Fatigue / chemically induced
Female
Humans
Middle Aged
Nausea / chemically induced
Serotonin Agents / administration & dosage*,  adverse effects*
Sexual Dysfunctions, Psychological / drug therapy*
Vomiting / chemically induced
Young Adult
Chemical
Reg. No./Substance:
0/Benzimidazoles; 0/Serotonin Agents; 37JK4STR6Z/flibanserin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Study of Ga(3+)-Induced Hydrothermal Crystallization of an ?-Quartz Type Ga(1-x)Fe(x)PO(4) Single Cr...
Next Document:  Effects of EPG treatment for English consonant contrasts on L2 perception and production.